Could a common anesthetic keep lung cancer from returning?
NCT ID NCT07347977
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether giving the anesthetic lidocaine during lung cancer surgery can reduce the chance of the cancer coming back. About 1,400 patients will be randomly assigned to receive lidocaine or a placebo. They will be followed for three years to track cancer recurrence and survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- lidocaine
- What this could lead to
- If it works, this could offer a simple, low-cost way to lower the risk of lung cancer coming back after surgery.
- What could go wrong
- This is an early-stage trial with no phase designation, and lidocaine's effect on cancer recurrence is unproven. Results may not show a clear benefit.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The first affiliated hospital of Ningbo University
Ningbo, Zhejiang, 315000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Could a bronchial wash detect lung cancer mutations faster?
- Can a targeted pill outsmart a tough lung cancer mutation?
- Can a PET scan reveal hidden heart harm from lung cancer treatment?